120 related articles for article (PubMed ID: 5003621)
1. Initial clinical trial of dibromodulcitol (NSC-104800) in patients with advanced cancer.
Keyes JW; Selawry OS; Hansen HH
Cancer Chemother Rep; 1971 Dec; 55(5):583-9. PubMed ID: 5003621
[No Abstract] [Full Text] [Related]
2. Clinical experiences with dibromodulcitol (NSC-104800) in solid tumors.
Phillips RW; Brook J
Cancer Chemother Rep; 1971 Dec; 55(5):567-73. PubMed ID: 4946081
[No Abstract] [Full Text] [Related]
3. Phase I study of dibromodulcitol (NSC-104800).
Andrews NC; Weiss AJ; Ansfield FJ; Rochlin DB; Mason JH
Cancer Chemother Rep; 1971 Feb; 55(1):61-5. PubMed ID: 5121653
[No Abstract] [Full Text] [Related]
4. Effects of combination therapy with bleomycin (NSC-125066) and dibromodulcitol (NSC-104800) on squamous cell carcinoma in man.
Onuma T; Holland JF; Sako K; Shedd DP
Cancer Chemother Rep; 1972 Oct; 56(5):625-33. PubMed ID: 4119907
[No Abstract] [Full Text] [Related]
5. [Clinical testing of Dibromdulcit in polycythemia vera].
Szentkláray J; Sellei C
Orv Hetil; 1971 Jun; 112(26):1523-5. PubMed ID: 4939990
[No Abstract] [Full Text] [Related]
6. Dibromodulcitol (NSC-104800)--clinical brochure.
Carter SK
Cancer Chemother Rep 3; 1968 Dec; 1(1):165-77. PubMed ID: 4989813
[No Abstract] [Full Text] [Related]
7. Phase I evaluation of dianhydrogalactitol (NSC-132313).
Haas CD; Stephens RL; Hollister M; Hoogstraten B
Cancer Treat Rep; 1976 May; 60(5):611-4. PubMed ID: 991150
[TBL] [Abstract][Full Text] [Related]
8. [Clinical experiences with Dibromdulcitol (DBD) in the treatment of cancer].
Nyiredy G; Gévai E
Bronches; 1971; 21(2):202-6. PubMed ID: 5126170
[No Abstract] [Full Text] [Related]
9. Dibromomannitol (NSC-94100): a clinical study of previously treated patients with refractory chronic myelocytic leukemia and blastic transformation.
Levin WC; Mims CH; Haut A
Cancer Chemother Rep; 1974; 58(2):223-8. PubMed ID: 4598242
[No Abstract] [Full Text] [Related]
10. Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Marsh JC; DeConti RC; Hubbard SP
Cancer Chemother Rep; 1971 Dec; 55(5):599-606. PubMed ID: 4334161
[No Abstract] [Full Text] [Related]
11. Clinical and pharmacologic experience with dibromodulcitol (NSC-104800). A new antitumor agent.
Sellei C; Eckhardt S; Horváth IP; Kralovánszky J; Institóris L
Cancer Chemother Rep; 1969 Dec; 53(6):377-84. PubMed ID: 4915082
[No Abstract] [Full Text] [Related]
12. Phase I trial of dianhydrogalactitol administered Iv in a weekly schedule.
Vogel CL; Winton EF; Moore MR; Sohner S
Cancer Treat Rep; 1976 Jul; 60(7):895-901. PubMed ID: 795538
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer.
Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK
Cancer Treat Rep; 1981; 65(5-6):517-9. PubMed ID: 7195306
[No Abstract] [Full Text] [Related]
14. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.
Perry MC; Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG
Cancer Treat Rep; 1976 Sep; 60(9):1247-50. PubMed ID: 797447
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of dibromohexitols.
Eckhardt S
Haematologica; 1972 Apr; 57(11):722-31. PubMed ID: 4200307
[No Abstract] [Full Text] [Related]
16. 1,2:5,6-Dianhydrogalactitol in advanced breast cancer.
Hoogstraten B; O'Bryan R; Jones S
Cancer Treat Rep; 1978 May; 62(5):841-2. PubMed ID: 657167
[No Abstract] [Full Text] [Related]
17. Cytosine arabinoside (NSC-63878)--clinical brochure.
Livingston RB; Carter SK
Cancer Chemother Rep 3; 1968 Dec; 1(1):179-205. PubMed ID: 4989814
[No Abstract] [Full Text] [Related]
18. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388).
Luce JK; Thurman WG; Isaacs BL; Talley RW
Cancer Chemother Rep; 1970 Apr; 54(2):119-24. PubMed ID: 4334086
[No Abstract] [Full Text] [Related]
19. A phase III study in lung carcinoma comparing hexamethyl-melamine (NSC 13875) to dibromodulcitol (NSC 104800) 1,2.
Wilson WL; Ryzin JV; Weiss AJ; Frelick RW; Moss SE
Oncology; 1975; 31(5-6):293-309. PubMed ID: 174041
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study.
Haas CD; Baker L; Thigpen T
Cancer Treat Rep; 1981; 65(1-2):115-7. PubMed ID: 6261943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
